Renal Insufficiency or Renal Failure &or End-stage Renal Disease Clinical Trial
Official title:
Cytokine Adsorption in Sepsis and Acute Kidney Injury
Aim of the study is to reduce the incidence of RIFLE stadium L and E after acute kidney injury in patients with severe sepsis/septic shock
Patient with proved severe sepsis/septic shock, treated in accordance to actual sepsis
guidelines, who develope akute kidney injury (RIFLE I) or kidney failure (RIFLE F), were
randomized in two groups.
One group is treated with CVVHD/ local citrat anticoagulation (standart clinical practice).
The other group ist treated with an additional cytokine adsorber ( 300ml CytoSorb device,
3804606CE01)
CytoSorb therapy is performed for 24h, then the adsorber is changed into a new device.
Cytosorb therapy is stopped, when Interleukin 6 leves drop below 1000 pg/ml in patient
serum.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment